Resilience

Resilience publishes blog posts about biologics and biotech manufacturing.

The page discusses challenges to wider adoption of nucleic acid-based medicines, which gained attention through COVID-19 mRNA vaccines.

The page explains that master cell banks (MCBs) are critical to scaling up and producing cell and gene therapies, biologics, and vaccines.

Resilience and Cytiva discuss how SA25 Aseptic Filling Workcells at Resilience’s Alachua, FL site can support drug product manufacturing operations.

Resilience offers careers in pharmaceutical biomanufacturing.

Resilience works in biopharmaceutical manufacturing, research and development, and regulatory science.

Resilience is a biomanufacturing CDMO improving access to complex medicines, with end-to-end solutions for safe & scalable biologics manufacturing.

The page describes how Resilience collects, uses, and protects personal information and outlines its privacy practices and data rights.

Website Terms of Service.

National Resilience divested its East Norriton site to Made Scientific as it sharpens its focus on biologics and sterile drug-product CDMO manufacturing.

Sep 2026 · National ResilienceNews article

National Resilience and Lilly announce a $750 million co-investment to expand U.S.-manufactured medicine supply and increase KwikPen output. They expect operations tied to the investment to begin in early 2027, supporting expanded production of medicines and KwikPens in the United States.

Jul 2026 · National ResilienceNews article

National Resilience announces that it is relocating its West Coast headquarters to Blue Ash, Ohio, with about 200 headquarters jobs. The company also announces an expansion of its sterile manufacturing capabilities.

Jun 2026 · National ResilienceNews article

National Resilience announces long-term financing of up to $825 million from OHA to accelerate its CDMO strategy. The financing supports plans to build out manufacturing in Cincinnati and Toronto.

Oct 2025 · National ResilienceNews article